Medivation, Inc., MDVN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Medivation, Inc., MDVN has a market cap of 10253.95. Since its IPO date on the 1/13/1997, Medivation, Inc., MDVN performance year to date is 28.47%. Today Medivation, Inc., MDVN has gained -1.02%, with a current price of 62.1.
Ownership of the company is 1.20% for insider ownership while institutional ownership is 92.40%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 21.50%, with return on investment at 27.10%.
In terms of debt levels and profit levels, Medivation, Inc., MDVN is seeing a long-term debt/equity of 0. While Total debt/equity is 0. With a profit margin of 25.40%, this is combined with a gross margin of *TBA, and operating margin of 40.20%. Medivation, Inc. ability to meet debt levels, with a current ratio of 4.2, while the quick ratio is 4.2.
For the last year Medivation, Inc., MDVN has seen a EPS growth of -11.10%. A performance for the year of 13.94%. The 52-week high is -1.40%, and the 52-week low is 135.14%. The average volume for Medivation, Inc., MDVN is 1387185.
With a target price of 64.06, can Medivation, Inc., MDVN reach this target? Looking at the value indicators of Medivation, Inc., MDVN. Medivation, Inc. has a P/E of 43.43 and a forward P/E of 28.29. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.24. Medivation, Inc. also has a P/S and a P/B of 10.29 and 11.33 respectively. For P/cash, Medivation, Inc. has a value of *TBA, while it is 34.11 for P/free cash flow.
At the current price of 62.1, Medivation, Inc. has a dividend yield of *TBA. We see a return on equity of 34.00%.
Looking more long-term Medivation, Inc., is projected to get an EPS growth for the next five years of 35.15%. In the short-term an EPS growth of 68.33% in the next year is forecasted. This is after a EPS growth of -11.10% for this year and for the last five years a 50.90% growth has been seen.